You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Discontinued ProductButylscopolammonium bromide (Cat. No. 0418) has been withdrawn from sale for commercial reasons.
Muscarinic antagonist. Antispasmodic.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
References are publications that support the biological activity of the product.
Pfaffendorf et al (1991) Comparison of various spasmolytic drugs on guinea-pig isolated common bile duct. Naunyn Schmiedebergs Arch.Pharmacol. 344 114 PMID: 1775188
Merck Index 12 1624
View Related Products by Product Action
Keywords: Butylscopolamine bromide, Butylscopolamine bromide supplier, Butylscopolamine, Non-selective, Muscarinics, 0418, Tocris Bioscience
Citations for Butylscopolammonium bromide
Citations are publications that use Tocris products.
Currently there are no citations for Butylscopolammonium bromide.
Reviews for Butylscopolammonium bromide
There are currently no reviews for this product. Be the first to review Butylscopolammonium bromide and earn rewards!
Have you used Butylscopolammonium bromide?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.